Brief: Mustang Bio Announces Updated Interim Results From Follicular Lymphoma Cohort Of Ongoing Phase 1/2 Clinical Trial Of MB-106, CD20-Targeted CAR T Therapy

Mustang Bio

13/06/2022 13:27

June 13 (Reuters) - Fortress Biotech Inc  FBIO.O :
    * MUSTANG BIO ANNOUNCES UPDATED INTERIM RESULTS FROM
FOLLICULAR
LYMPHOMA COHORT OF ONGOING PHASE 1/2 CLINICAL TRIAL OF MB-106,
CD20-TARGETED CAR T THERAPY
    * MUSTANG BIO INC - 94% OVERALL RESPONSE RATE AND 78%
COMPLETE
RESPONSE RATE IN PATIENTS WITH FL
    * MUSTANG BIO - 100% ORR IN OTHER B-CELL NON-HODGKIN
LYMPHOMAS
INCLUDING WALDENSTROM MACROGLOBULINEMIA AND DIFFUSE LARGE B-CELL
LYMPHOMA
    * MUSTANG BIO INC -  UPDATED INTERIM DATA FROM ONGOING PHASE
1/2
CLINICAL TRIAL OF MB-106 SHOW A FAVORABLE SAFETY PROFILE
    * MUSTANG BIO INC - ADDITIONALLY, 17% EXPERIENCED A PARTIAL
RESPONSE AND 5% EXPERIENCED DISEASE PROGRESSION
    * MUSTANG BIO INC - ONE PATIENT EXPERIENCED
PSEUDO-PROGRESSION
FOLLOWED BY A SPONTANEOUS CR DOCUMENTED AT 207 DAYS AND HAS
REMAINED IN REMISSION SINCE
    * MUSTANG BIO INC - ADDITIONALLY, ONE PATIENT WITH PRIOR
CD19
CAR-T FAILURE EXPERIENCED A CR AND ALSO REMAINS IN REMISSION

Source text for Eikon:  ID:nGNX9ZF3Xs 
Further company coverage:  FBIO.O 

 ((Reuters.Briefs@thomsonreuters.com;))